ALIMTA® Extends Survival in Continuation Maintenance Setting for Specific Lung Cancer Patients (via redOrbit)
INDIANAPOLIS, Oct. 17, 2012 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that patients may receive ALIMTA(®) (pemetrexed for injection) as a maintenance therapy following first-line ALIMTA plus cisplatin for locally advanced or metastatic nonsquamous non-small cell lung cancer…
No comments:
Post a Comment